undamentalytics Newsletter

Freund John Gordon: insider trades

Director at 4 companies we cover. No open-market purchases and 20 sales not made under a pre-set plan, reported from October 29, 2014 to May 18, 2026.

What happened after Freund John Gordon’s sales?

After their sales, the shares moved −15.0% against the index over 12 months on average (a negative figure means selling was the right call); 74% trailed it.

With 296 insiders tested, some will look skilled or unskilled by chance alone: when we replaced each insider’s stocks with random companies bought on the same days, about 5.7 cleared the bar ahead and 23.3 behind. One record on its own proves little.

Trade by trade

Freund John Gordon: trades against the S&P 500 afterwards
MeasuredTrades countedAverage vs S&P 500MedianWent the right wayYearst-statisticp-valueEvidence
Purchases, 3 months after the report 0 — — — — — — Not enough years
Purchases, 6 months after the report 0 — — — — — — Not enough years
Purchases, 12 months after the report 0 — — — — — — Not enough years
Purchases, 12 months after the trade 0 — — — — — — Not enough years
Sales, 3 months after the report 20 +8.5% −4.4% 55% 7 −0.19 0.86 No reliable evidence
Sales, 12 months after the report 19 −15.0% −35.2% 74% 6 −1.10 0.32 No reliable evidence
Sales, 12 months after the trade 19 −13.3% −13.0% 74% 6 −1.02 0.35 No reliable evidence

“Average vs S&P 500” is the stock’s return including dividends minus the index’s over the same dates, from the close on the first trading day after the report, or from the close on the trade date. Only windows that have finished are counted. For sales, a negative figure means the stock lagged after it was sold, so selling was the right call (green). “Went the right way” is the share of purchases that beat the index, or of sales that trailed it. The t-statistic uses one average per year of reports, because one person’s trades bunch into the same stock and weeks, and needs trades in at least four different years; the p-value comes from the t distribution with that number of years (with four years, a t of 2 has p = 0.14). “Some evidence” means p under 5%, “strong evidence” p under 1% over at least six years.

Companies traded

CompanyTitle on the latest filingPurchasesSalesFirst reportLatest report
Si-bone, Inc. SIBN —013August 14, 2019August 11, 2025
Sutro Biopharma, Inc. STRO —03August 21, 2020September 22, 2020
Collegium Pharmaceutical, Inc COLL —03June 11, 2025May 18, 2026
Protara Therapeutics, Inc. TARA —01October 29, 2014October 29, 2014

Trades and what followed

Moves are against the S&P 500; green means the trade went the insider’s way.

ReportedTradedCompanyTradeValue3 months after report12 months after report12 months after trade
May 18, 2026May 15, 2026 COLL Sale $142,547 −19.6%not yetnot yet
August 12, 2025August 8, 2025 COLL Sale $400,603 +12.2%−47.2%−47.9%
August 11, 2025August 8, 2025 SIBN Sale $193,991 −3.2%+2.3%−2.4%
June 11, 2025June 9, 2025 COLL Sale $202,123 +16.9%−11.0%−8.0%
August 11, 2023August 9, 2023 SIBN Sale $616,200 −24.7%−59.4%−52.1%
June 16, 2021June 14, 2021 SIBN Sale $1,627,418 −30.8%−47.3%−45.4%
June 1, 2021May 27, 2021 SIBN Sale $2,174,845 −24.8%−49.3%−52.1%
May 26, 2021May 24, 2021 SIBN Sale $2,261,513 −32.3%−52.1%−53.3%
March 18, 2021March 16, 2021 SIBN Sale $21,913,663 −15.6%−56.1%−46.2%
March 15, 2021March 11, 2021 SIBN Sale $7,343,123 −5.7%−46.2%−40.0%
December 4, 2020December 2, 2020 SIBN Sale $3,448,054 +18.6%−42.8%−43.1%
October 20, 2020October 19, 2020 SIBN Sale $4,181,166 +26.8%−35.2%−36.0%
September 22, 2020September 18, 2020 STRO Sale $4,800,000 +99.5%+51.2%+28.4%
September 15, 2020September 11, 2020 STRO Sale $5,000,000 +91.7%+47.5%+59.8%
August 21, 2020August 19, 2020 STRO Sale $4,360,000 +98.4%+97.4%+67.2%
August 14, 2020January 27, 2020 SIBN Sale $21,500,000 +7.9%−36.9%+21.5%
August 27, 2019August 26, 2019 SIBN Sale $2,804,602 −17.7%−11.7%−13.0%
August 23, 2019August 21, 2019 SIBN Sale $958,509 −18.1%−13.0%−12.7%
August 14, 2019August 12, 2019 SIBN Sale $7,300,000 −12.9%−5.2%−8.9%
October 29, 2014October 27, 2014 TARA Sale $560,380 +2.3%+30.6%+30.9%

Open-market purchases and sales of at least $10,000 in companies we cover, from SEC Form 4 filings; sales made under a pre-set Rule 10b5-1 plan are not shown. “Not yet” means the window has not finished or the share price was under $5 at entry. These are the shares’ moves after each trade: they say nothing about why Freund John Gordon traded and do not suggest the use of non-public information. How every insider compares · the insider trading backtest.